☆ 4.5 Article

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

ARTHRITIS & RHEUMATOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Rheumatology

Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials

Ian N. Bruce et al.

Summary: This study evaluated the effects of sustained glucocorticoid tapering in patients with SLE. The results showed that sustained glucocorticoid tapering is associated with reduced glucocorticoid dosage, improved patient-reported outcomes, and fewer adverse events. Treatment with anifrolumab has the potential to reduce disease activity and glucocorticoid exposure.

RHEUMATOLOGY (2023)

添加到收藏夹

Letter Rheumatology

Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian et al

Quirin Notz et al.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Manuel Francisco Ugarte-Gil et al.

Summary: The severity of COVID-19 outcomes in individuals with SLE is associated with factors such as gender, age, steroid dosage, comorbidities, and the activity of SLE.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

Bo Meng et al.

Summary: The Omicron variant of SARS-CoV-2 has a higher affinity for ACE2 and can evade neutralizing antibodies more effectively compared to the Delta variant. A third dose of mRNA vaccine can provide enhanced protection. Omicron has lower replication in lung and gut cells and less efficiently cleaves its spike protein compared to Delta.

NATURE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

Rigel Suzuki et al.

Summary: The Omicron variant of SARS-CoV-2 has spread rapidly in several countries and has shown lower fusogenicity and attenuated pathogenicity compared to the Delta variant.

NATURE (2022)

添加到收藏夹

Article Rheumatology

Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials

Eric F. Morand et al.

Summary: This post-hoc analysis aimed to evaluate the efficacy of anifrolumab on organ domain-specific SLE disease activity. The results demonstrated that anifrolumab treatment improved multiple organ systems in SLE patients, particularly the musculoskeletal system, mucocutaneous system, and immunological system.

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

Fengchun Zhang et al.

Summary: The study evaluated the long-term safety and efficacy of belimumab in Chinese patients with SLE. The results showed favorable safety profile and disease control for up to 6 years, consistent with previous studies on belimumab.

RMD OPEN (2022)

添加到收藏夹

Article Rheumatology

Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab

Vibeke Strand et al.

Lancet Rheumatology (2022)

添加到收藏夹

Review Rheumatology

A glimpse into the future of systemic lupus erythematosus

Martin Aringer et al.

Summary: This viewpoint article provides a forecast of clinically meaningful changes in the management of systemic lupus erythematosus (SLE) over the next 10 years. The article suggests significant advancements in diagnosis and treatment, including the use of musculoskeletal sonography for assessing lupus arthritis, polyomics studies to unravel the immune mechanisms of the disease, and the application of biomarkers for predicting therapeutic success.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2022)

添加到收藏夹

Article Rheumatology

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

Yoshiya Tanaka et al.

Summary: The study showed that belimumab had a favorable safety profile and treatment responses in patients with systemic lupus erythematosus from Japan and South Korea for up to 7 years.

RMD OPEN (2021)

添加到收藏夹

Editorial Material Rheumatology

Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study Comment

Renaud Felten et al.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Medical Laboratory Technology

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Ruth Fernandez-Ruiz et al.

Summary: In light of the COVID-19 pandemic, assessing its impact on patients with autoimmune rheumatic diseases, specifically systemic lupus erythematosus, is crucial. Patients with SLE present unique considerations due to their use of immunosuppressants and potential susceptibility factors like organ damage from SLE. Research on SLE may offer insights into immune responses seen in severe cases of COVID-19.

TRANSLATIONAL RESEARCH (2021)

添加到收藏夹

Article Rheumatology

Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study

W. Winn Chatham et al.

Summary: Long-term treatment with anifrolumab shows acceptable safety profile and sustained improvement in disease activity, health-related quality of life, and serologic measures for patients with moderate-to-severe systemic lupus erythematosus.

ARTHRITIS & RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus

Richard Furie et al.

Summary: The analysis of pooled data from the TULIP-1 and TULIP-2 trials supports that anifrolumab reduces flares and allows for glucocorticoid tapering in patients with SLE, especially for those who successfully taper to <= 7.5 mg/day.

LUPUS (2021)

添加到收藏夹

Article Rheumatology

FDA approval for anifrolumab in patients with lupus

Talha Khan Burki

Lancet Rheumatology (2021)

添加到收藏夹

Review Rheumatology

Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies

Manuel Francisco Ugarte-Gil et al.

Summary: This study confirmed associations between GC use and three specific damage items, suggesting that in treating patients with SLE, the goal should be to maximize the efficacy of GC while minimizing their harms.

LUPUS SCIENCE & MEDICINE (2021)

添加到收藏夹

Article Rheumatology

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

Raj Tummala et al.

Summary: In a pooled analysis of 925 patients with moderate to severe SLE, monthly intravenous anifrolumab 300 mg was generally well tolerated over 52 weeks with an acceptable safety profile. Anifrolumab was associated with an increased incidence of herpes zoster and respiratory tract infections, but a lower reported rate of SLE worsening as serious adverse events.

LUPUS SCIENCE & MEDICINE (2021)

添加到收藏夹

Article Rheumatology

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension

Ronald F. van Vollenhoven et al.

RHEUMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Immunology

Activity Disease in SLE Patients Affected IFN-γ in the IGRA Results

Winni Maharani et al.

JOURNAL OF INFLAMMATION RESEARCH (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Paul Bastard et al.

SCIENCE (2020)

添加到收藏夹

Letter Rheumatology

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Alexis Mathian et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Article Rheumatology

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial

Richard A. Furie et al.

LANCET RHEUMATOLOGY (2019)

添加到收藏夹

Article Rheumatology

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

Kerry A. Casey et al.

LUPUS SCIENCE & MEDICINE (2018)

添加到收藏夹

Article Rheumatology

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

Jeffrey M. Riggs et al.

LUPUS SCIENCE & MEDICINE (2018)

添加到收藏夹

Article Rheumatology

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

Richard Furie et al.

ARTHRITIS & RHEUMATOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Effects of annual influenza vaccination on morbidity and mortality in patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study

Chi-Ching Chang et al.

Scientific Reports (2016)

添加到收藏夹

Article Rheumatology

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Ian N. Bruce et al.

ANNALS OF THE RHEUMATIC DISEASES (2015)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.